Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Evaluation of beta-2′-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer

A Southwest Oncology Group Study

Gagliano, B. G., MD.a; Panettiere, F. J., M.D.b; Haas, C. D., M.D.c; Baker, I., D.O.d; Hewett, J., M.D.; Stuckey, W. J., M.D.f; O'Bryan, R. M., M.D.g; Bottomley, R., M.D.h; Heilburn, L. K., Ph.D.i

American Journal of Clinical Oncology: January 1981 - Volume 4 - Issue 4 - p 401–406

TWO HUNDRED TWENTY EUIGIBLE PATIENTS with metistatic colorectal carcinoma were treated with a combination of brta-2‘-deoxythioguanosine (BTG). plus methyl-CCNU or mitomycin. There was no significant difference in overall response (CR/PR + stable) among fully evaluable patients between the mitomycin plus BTG are 19/96 (19.7%) and the MeCCNU arm 26/87 (29.8%) Median survival of eligible patients was 19 weeks with mitomycin plus BTG versus 21 weeks with MeCCNU plus RTG no difference Median survival of responders (40 weeks) and patients with stable disease (35 weeks) was significantly better than patients with increasing disease (17 weeks): p + 0.001.

a Tular University (Satellite Las Vegas). New Orleans. Louisiana.

b University of Arkansas for Medical Sciences. Little Rock. Arkaness.

c University of Kansas Medical Center, Kansas City.

d Wayne State University School of Medicine. Detroit. Michigan.

e Clevland Clinic Foundation. Cleveland. Ohio.

f Tularv University School of Medicine, New Orleans. louisiana.

g Henry Ford Hospital. Detroit. Michigan.

h Oklahoma Medical Research Foundation Oklahoma City, Oklahoma

i M. D. Anderson Hospital, Houston, Texas.

© Lippincott-Raven Publishers.